Peptimmune, a Cambridge, Mass.-based biotechnology company, completed a second close on its Series D venture backing, worth $8.9 million. The round was led by New
Peptimmune, a Cambridge, Mass.-based biotechnology company, completed a second close on its Series D venture backing, worth $8.9 million. The round was led by New
Copyright PEI Media
Not for publication, email or dissemination
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.